Nektar Therapeutics Downgraded by Zacks to “Neutral” (NKTR)
Nektar Therapeutics (NASDAQ:NKTR) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, American Banking News reports. They currently have a $14.90 target price on the stock. Zacks‘ target price suggests a potential upside of 17.23% from the stock’s previous close.
Nektar Therapeutics (NASDAQ:NKTR) traded down 1.57% during mid-day trading on Wednesday, hitting $12.51. The stock had a trading volume of 587,266 shares. Nektar Therapeutics has a one year low of $8.70 and a one year high of $14.47. The stock has a 50-day moving average of $12.3 and a 200-day moving average of $11.6. The company’s market cap is $1.453 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Brean Capital raised their price target on shares of Nektar Therapeutics from $14.00 to $18.00 in a research note to investors on Monday. Analysts at Piper Jaffray initiated coverage on shares of Nektar Therapeutics in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $20.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Nektar Therapeutics has an average rating of “Buy” and an average target price of $14.99.
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.